Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $9.00 price target.
Thomas Shrader has given his Buy rating due to a combination of factors that indicate a promising future for Esperion. One of the key reasons is the company’s potential to achieve profitability by late 2025, driven by a significant increase in Medicare patients willing to pay out-of-pocket costs, which suggests sustained demand for their products. Additionally, Esperion is exploring the development of a triple pill, which could enhance their product offerings and maintain engagement with healthcare providers.
Moreover, Esperion’s strategic partnerships for global expansion, such as those with NeoPharm and CSL, are expected to bolster their market presence in regions like Israel and Australia/New Zealand. These partnerships not only expand their reach but also provide opportunities for milestone payments and royalties. The positive real-world results from the MILO study further support the efficacy of their bempedoic acid franchise, which could drive future growth. Overall, these strategic initiatives and financial metrics contribute to Shrader’s optimistic outlook on Esperion’s stock.
Shrader covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Arcturus Therapeutics, and Verona Pharma. According to TipRanks, Shrader has an average return of 4.3% and a 36.08% success rate on recommended stocks.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $4.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com